SA

Saroja Appannagari

Active Director Director DIN 10833318
DIN 10833318 First appointment Nov 2024 Primary industry Paper
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Nov 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Saroja Appannagari

Data last updated:

Saroja Appannagari is a Director at Zillion-Biotech Limited (since 2024). The company operates in Paper.

DIN 10833318
Primary Designation Director
Industry Paper
First Appointment 11 Nov 2024
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Zillion-Biotech Limited U21001TS2024PLC190849
Director11 Nov 20242024Active

Directorship timeline

Open interactive timeline →
Zillion-Biotech Limited
Premium access

Shareholding and investment profile for Saroja Appannagari

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Saroja Appannagari

Saroja Appannagari currently holds 1 directorship: Zillion-Biotech Limited (Director, since 11 Nov 2024).

Saroja Appannagari was first appointed on 11 Nov 2024 as Director at Zillion-Biotech Limited.

The current boards of Saroja Appannagari's companies include Appanagari Pradeep Aakarsh Kulkarni (Zillion-Biotech Limited), Bhagya Lakshmi Battu (Zillion-Biotech Limited), Munnangi Jayalakshmi (Zillion-Biotech Limited), Munnangi Kumar Ravi (Zillion-Biotech Limited), Srinivas Rao Kondapavuluri (Zillion-Biotech Limited), Thara Panchakshari Maguluri (Zillion-Biotech Limited), among others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available